^
    Back
    Association details:
    Biomarker:PALB2 mutation
    Cancer:Pancreatic Adenocarcinoma
    Drug:Rubraca (rucaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    02/24/2022
    Excerpt:
    Pancreatic Adenocarcinoma...Useful in certain circumstances...Rucaparib (for germline or somatic BRCA1/2 or PALB2 mutations)
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

    Excerpt:
    ...- Documented deleterious BRCA1/2 or PALB2 mutation (germline or somatic) as assessed by CLIA certified laboratory....
    Trial ID:
    NCT03140670